UCB Dividendos y recompras
Dividendo controles de criterios 0/6
UCB es una empresa que paga dividendos con una rentabilidad actual de 0.6%.
Información clave
0.6%
Rentabilidad por dividendo
0.3%
Rendimiento de la recompra
| Rendimiento total para el accionista | 0.9% |
| Rendimiento futuro de los dividendos | 0.6% |
| Crecimiento de los dividendos | 2.6% |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | 18% |
Últimas actualizaciones de dividendos y recompras
Recent updates
Actualización de narrativa • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
Actualización de narrativa • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.Actualización de narrativa • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.Actualización de narrativa • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.Actualización de narrativa • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
Actualización de narrativa • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.Actualización de narrativa • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.Actualización de narrativa • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.Actualización de narrativa • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.Actualización de narrativa • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.Actualización de narrativa • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.Actualización de narrativa • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.Actualización de narrativa • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.Artículo de análisis • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Actualización de narrativa • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.Actualización de narrativa • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.Artículo de análisis • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...Actualización de narrativa • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.Actualización de narrativa • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.Actualización de narrativa • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.Artículo de análisis • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
Nueva narrativa • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: UCB no paga un dividendo notable para el mercado Belgian, por lo que no es necesario comprobar si los pagos son estables.
Dividendo creciente: UCB no paga un dividendo notable para el mercado Belgian, por lo que no es necesario comprobar si los pagos aumentan.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de UCB vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (UCB) | 0.6% |
| Suelo de mercado 25% (BE) | 2.4% |
| Techo de mercado 25% (BE) | 6.5% |
| Media de la industria (Pharmaceuticals) | 2.7% |
| Analista de previsiones (UCB) (hasta 3 años) | 0.6% |
Dividendo destacado: El dividendo de UCB(0.6%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado Belgian (2.39%).
Alto dividendo: El (0.6%) del dividendo de UCB es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Belgian (6.53%).
Pago de beneficios a los accionistas
Cobertura de los beneficios: UCB no paga un dividendo notable para el mercado Belgian.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: UCB no paga un dividendo notable para el mercado Belgian.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 03:35 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
UCB SA está cubierta por 40 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |